© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Lisa Larkin, MD, FACP, MSCP, IF
Articles
New Menopause Therapies Reflect a “Sea Change” in Women’s Health, Says Lisa Larkin, MD
December 02, 2025
Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.
Breaking the Silence: Discussing Menopause Treatment Options in Primary Care
November 21, 2025
Lisa Larkin, MD, discusses how social media is driving menopause awareness and why primary care physicians must educate themselves to meet patient demand.
Treatment of Vasomotor Symptoms: From Hormone Therapy to Neurokinin Receptor Antagonists
November 20, 2025
Larkin Larkin, MD, reviews treatment options for VMS, comparing hormone therapy effectiveness with antidepressants and new neurokinin antagonists.
Lisa Larkin, MD, on the Importance of Recognizing and Managing Vasomotor Symptoms in Menopause
November 17, 2025
Women increasingly seek evidence-based menopause care as awareness grows, yet many still suffer from untreated vasomotor symptoms.
Lisa Larkin, MD: Elinzanetant Offers a “Game-Changing” Option for Menopause Care in Primary Care
November 05, 2025
Lisa Larkin, MD, discusses how elinzanetant may change menopause management for women who can’t use hormone therapy and what PCPs need to know.
Guidance for PCPs: Streamlining Menopause Care
November 25, 2024
Panelists discuss strategies for simplifying complex information for primary care physicians (PCPs), provide tips on how PCPs can effectively communicate evidence-based treatment options to patients, and outline actionable points and key takeaways to enhance patient care in managing menopause symptoms.
Nonestrogen Treatments for Menopause
November 25, 2024
Panelists discuss alternative therapies for women who are not candidates for or choose not to use hormonal therapy, review nonhormonal treatment options recommended by the North American Menopause Society, and explore the growing importance of Level I evidence and consensus opinions in creating a more holistic view of available therapies, both hormonal and nonhormonal.
VMS Treatment Guidelines
November 25, 2024
Panelists discuss key considerations for women taking hormonal therapy, emphasizing the importance of individualized treatment plans and shared decision-making to evaluate the risk-benefit profile of therapy.
Malignancy Risks of Neurokinin Receptor Antagonists
November 25, 2024
Panelists discuss clinical trial data suggesting a small but higher incidence of endometrial hyperplasia or malignancy with fezolinetant, while no cases of endometrial hyperplasia or malignancy were observed with elinzanetant in a long-term safety study.
Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant
November 25, 2024
Panelists discuss why elinzanetant is likely to be associated with a lower risk of liver injury due to its distinct molecular structure compared to fezolinetant, and compare the adverse event profiles of the 2 drugs, highlighting that elinzanetant is more commonly associated with headache and fatigue while fezolinetant is linked to abdominal pain, diarrhea, insomnia, and back pain.